28 Feb 2022 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx to Present at ILD Summit 2022
RXC007 reduced lung fibrosis in murine and rat models and suppresses pro-fibrotic protein and gene expression in human PCLS models
Alderley Park, 28 February 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that Nicolas Guisot, Research Fellow at Redx, will present an overview of the clinical development of the Company's lead fibrosis asset, RXC007, at the forthcoming Virtual Interstitial Lung Disease Drug Development (ILD) Summit, 7-9 March 2022. The drug candidate is currently in a Phase 1 healthy volunteer study, with Phase 2 studies for idiopathic pulmonary fibrosis expected to commence later in 2022.
RXC007 is an orally bioavailable selective ROCK2 (Rho Associated Protein Kinase 2) inhibitor with potential for development in multiple fibrotic conditions. ROCK2 is a clinically validated target that has been shown to sit at a key junction that regulates various cell signalling pathways central to fibrosis. As a selective ROCK2 inhibitor, RXC007 has the potential to treat several fibrotic diseases, including interstitial lung disease, and has demonstrated robust anti-fibrotic effects in a range of in vivo preclinical models.
The presentation at the ILD Summit will focus on the rationale for ROCK2 inhibition in the treatment of lung fibrosis and its potential to address the current high unmet need. Nicolas will also discuss the development of RXC007 and review the compelling data generated in preclinical studies.
Title: | Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis |
Day/Date: |
Wednesday 9 March 2022 |
Presentation Time: |
16:00 - 16:30 EST |
RXC007 is one of two development candidates that Redx has progressed in the area of fibrosis. The second, RXC006, a novel, orally available porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis, is being progressed in Phase 1 studies by AstraZeneca following a partnership deal in August 2020.
For further information, please contact: |
|
|
| |
|
|
|
| |
Redx Pharma Plc ir@redxpharma.com
UK Headquarters Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 | |||
US Office Peter Collum, Chief Financial Officer |
| |||
|
| |||
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 | |||
Matt Davis/ Adam Dawes |
| |||
|
| |||
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 | |||
Claes Spång/ Satheesh Nadarajah/ David Wilson |
| |||
|
| |||
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 | |||
Rupert Dearden/ Freddy Crossley/ Emma Earl |
| |||
|
| |||
FTI Consulting | T: +44 (0)203 727 1000 | |||
Simon Conway/ Ciara Martin |
| |||
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/